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Abstract: A new hypothesis highlights sleep-dependent learning/memory consolidation and regards
the sleep-wake cycle as a modulator of β-amyloid and tau Alzheimer’s disease (AD) pathologies.
Sundowning behavior is a common neuropsychiatric symptom (NPS) associated with dementia.
Sleep fragmentation resulting from disturbances in sleep and circadian rhythms in AD may have
important consequences on memory processes and exacerbate the other AD-NPS. The present
work studied the effect of training time schedules on 12-month-old male 3xTg-AD mice modeling
advanced disease stages. Their performance in two paradigms of the Morris water maze for spatial-
reference and visual-perceptual learning and memory were found impaired at midday, after 4 h of
non-active phase. In contrast, early-morning trained littermates, slowing down from their active
phase, exhibited better performance and used goal-directed strategies and non-search navigation
described for normal aging. The novel multitarget anticholinesterasic compound AVCRI104P3
(0.6 µmol·kg−1, 21 days i.p.) exerted stronger cognitive benefits than its in vitro equipotent dose
of AChEI huprine X (0.12 µmol·kg−1, 21 days i.p.). Both compounds showed streamlined drug
effectiveness, independently of the schedule. Their effects on anxiety-like behaviors were moderate.
The results open a question of how time schedules modulate the capacity to respond to task demands
and to assess/elucidate new drug effectiveness.
Keywords: sleep; circadian activity; protocols; behavior; drug assessment; aging; Alzheimer’s
disease; BPSD; AChEI; multitarget compounds; disease-modifying mechanisms
1. Introduction
The new hypothesis on the physiological function of sleep highlights sleep-depending
learning and memory consolidation [1] and associated plasticity, as well as their strong
implications on skill performance involved in many daily life activities [2]. Similarly, visual
discrimination learning requires sleep after training [3], and early sleep triggers memory
for early visual discrimination skills [4]. Through the life cycle, whereas adequate sleep
in childhood and beyond is important for development [5,6], new evidence supports the
relevance of the sleep-wake cycle in aging but also since early pre-symptomatic stages of
Alzheimer’s disease (AD) [7–10]. At the pathological level, the sleep-awake cycle controls
Aβ levels [11], to the extent that it is regarded as a modulator of AD pathogenesis, while
sleep disturbances are proposed as a predictor of dementia and Aβ pathology [12]. The
most recent of these outstanding works show that the interstitial fluid and cerebrospinal
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levels of tau are also regulated by the sleep-wake cycle. Indeed, sleep deprivation increases
the levels of tau and the spread of tau pathology [13]. These frequent sleep disturbances,
with awakenings during the night and increased proclivity to sleep during daytime [14–16],
are referred to as sundowning behavior, one of the most common co-morbid clinical
manifestations associated with AD. Sleep fragmentation as a result of disturbances in sleep
and circadian rhythms in AD may have not only important consequences on memory
processes [5,17], but it may also exacerbate the other neuropsychiatric symptoms (NPS)
associated with dementia [18], since the impact of sleep in mood disorders, such as anxiety
and depression, is also well known and vice versa.
At the translational level, among the different animal models for AD, homozygous
3xTg-AD mice created by LaFerla [19] show a noticeable NPS-like profile, also mimicking
diurnal rhythm disturbances [20–25]. These animals are sensitive to sleep restriction [26]
and display a severe impairment of the functioning of the clock gene pathway [27,28], with
males exhibiting worse circadian rhythm disruptions than females [28]. We have recently
shown that they have altered slow and fast neocortical oscillations [29]. Therefore, this
animal model is useful to investigate whether the alterations of their circadian activity may
modify their cognitive performance and the sensitivity of behavioral tests aimed to assess
the therapeutic efficacy of new drugs.
Except for those studies of circadian activity, research in the rodents’ natural active
dark cycle or using inverted cycle has scarcely been addressed, mostly due to practical
reasons. To avoid influences of the time of the day, most behavioral research is usually done
during the morning, their non-active circadian period [20]. However, on several occasions,
we noticed that cognitive performance of 3xTg-AD mice, but not that of WT mice [30],
was sensitive to the time schedules used for training and testing. We hypothesized that
early morning was not optimal to observe their impaired cognitive profile in the Morris
water maze.
On the other hand, the complexity of AD has led to drug development of multitar-
get compounds concurrently interfering with different mechanisms, aiming to provide
symptomatic relief and exerting disease-modifying benefits [31,32]. In this sense, our
multidisciplinary research consortium has synthesized and evaluated the pharmacolog-
ical profile of new AChEIs, tacrine-huperzine A hybrids, and their derivatives of po-
tential interest for the treatment of AD [33]. Among these, huprines and derivatives
have been successfully characterized. Huprine X (HX), a reversible AChE inhibitor
hybrid of tacrine and huperzine A, affects the amyloidogenic process in vitro and the
AD-related neuropathology in vivo in mice models of AD [34–42]. More recently, we
have shown that a new family of donepezil-huprine heterodimers that display a dual
site binding within AChE has been synthesized, and these compounds have shown
inhibitory a highly potent and selective inhibitory action on AChE and BChE. More-
over, they inhibit AChE-induced and self-induced β-amyloid (Aβ) aggregation and β-
secretase (BACE-1), and these new drugs are able to cross the blood-brain barrier. Among
them, AVCRI104P3 ((±)-3-chloro-12-[(3-{4-[(5,6-dimethoxyindan-2-yl)methyl]piperidin-1-
yl}propyl)amino]-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinoline) has
shown an interesting pharmacological profile. It is a potent in vitro inhibitor of human
AChE and moderately potent inhibitor of human BChE, AChE-induced, and self-induced
Aβ aggregation, and BACE-1 [30].
Therefore, in the present work, we investigated the impact of early morning and mid-
day training schedules on the cognitive performance of male 3xTg-AD mice at 12 months of
age, modeling neuropathological advanced disease stages [43]. Since 3xTg-AD mice exhibit
circadian rhythm disturbances with sex preference, males were used for the present work
purposes [28]. The hypothesis also considered the effect of chronic treatment with anti-
Alzheimer compounds [44,45]. AVCRI104P3 is a novel multitarget compound endowed
with potent in vitro inhibitory activity of human AChE and moderately potent inhibitory
activity of human butyrylcholinesterase (BChE), AChE-induced and self-induced Aβ aggre-
gation, and BACE-1, which has shown behavioral [30,46] and neuroprotective effects [47]
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in middle-aged mice. For the sake of comparison, we used HX, a potent reversible AChE in-
hibitor that affects the amyloidogenic process in vitro, and the AD-related neuropathology
and behavior in mice models of AD [47].
2. Materials and Methods
Forty-two 12-month-old homozygous male mice from the Spanish colony of 3xTg-AD
mice genetically engineered at the University of California Irvine were used [19]. Subjects
were housed in Macrolon cages under standard laboratory conditions of food and water
ad libitum, 22 ± 2 ◦C, 60 ± 10% relative humidity, and a 12/12 h light-dark cycle with
lights on at 8:00 a.m. To confirm the findings, two independent experimental sets (March,
April) were studied in a counterbalanced manner and blind to the experiment. All animals
were treated according to protocols approved by the Department of the Environment
and Housing (DMAH, Generalitat de Catalunya, Spain) on 16 March 2014 (certificate No:
DMAH-7981). All the research was conducted in compliance with the Spanish legislation
on “Protection of Animals Used for Experimental and Other Scientific Purposes” and in
accordance with the EU Directive (2010/63/UE) on the NC 3Rs and the efforts to reduce





were synthesized as previously described [33,37]. Littermates housed together were dis-
tributed into the different groups (n = 14/group) and received chronic treatment (i.p.,
1 mL/kg) with either HX (0.12 µmol kg−1), AVCRIP104P3 (0.6 µmol kg−1) or the vehicle
(saline) for 21 days, at 3:00 p.m. daily, so that behavioral analysis could be done without
interference during the mornings. The chosen doses were those previously used in in vivo
studies, shown to exert beneficial effects in middle-aged animals with distinct effectivity at
the cognitive and non-cognitive levels [30].
2.2. Side Effects and NPS-Like Behaviors
Physical condition, weight, and presence/absence of adverse effects, such as diarrhea
and tremulous jaw movements, were monitored daily during treatment. Side effects on the
locomotor activity were assessed in the classical open-field (OF) test (as compared to basal
levels, day 0), as previously detailed [30].
2.3. Behavioral Assessment
Cognitive performance was assessed in three learning and memory paradigms in
the Morris water maze. Furthermore, the same animals were assessed for exploratory
activity and anxiety-like behaviors using the dark-light box and corner test, as previously
described [30].
2.3.1. Exploratory Activity and Anxiety-Like Behaviors
Briefly, locomotor activity, anxiety-like behaviors, and emotionality were assessed by
placing the animals in the center of an open-field (woodwork, white, 50 × 50 × 35 cm height,
5 × 5 squares) and observed for 5 min. The latencies to leave the center (central square),
reach the peripheral zone (wide square ring next to the walls), and perform the first rearing
were noted. Horizontal (number of crossings) and vertical (number of rearings) locomotor
activity, the number and duration of grooming, the number of defecations, and urination
presence were also recorded. The apparatus was cleaned thoroughly before testing the
following animal. Anxiety-like behavior was also measured in the dark/light box. The
apparatus (Panlab, S.L., Barcelona, Spain) consisted of two compartments (black, 27 × 18
× 27 cm, white, 27 × 27 × 27 cm, lit with a 20 W white bulb) connected by an opening
(7 × 7 cm). The mice were introduced into the black compartment and observed for 5 min.
Brain Sci. 2021, 11, 426 4 of 12
Latency to enter (all four paws) the lit compartment, the time spent in the lit compartment,
and the horizontal (3 × 3 squares) and vertical (rearings) activities developed once they
were recorded. The apparatus was cleaned thoroughly before testing the following animal.
Finally, neophobia to a new home-cage was assessed by introducing the animals into the
center of a standard cage filled with 2 L of clean wood cuttings. One cage was used per
animal. The number of visited corners and number of rearings were recorded for 30 s.
2.3.2. Morris Water Maze (MWM)
The effects of training and test time schedules as well as those of AVCRI104P3 and
HX drugs were assessed from day 15 to 21, after the start of treatment, and compared
to saline-treated littermates. In each treatment group, half of the animals were trained
to locate a platform (7 cm diameter) in a circular pool (Intex Recreation Corp. CA, USA;
91 cm diameter; 20 cm height, 25 ◦C opaque water) located in a black test room with
distal cues, early in the morning (from 9 to 10 a.m.) and the other half were trained at
midday (from 12 to 1 p.m.). Three paradigms were used as previously described [30]:
First, we assessed short- and long-term spatial reference learning and memory (6 days,
4 trials 15 min apart, 6 days of place task (PT1-PT6), followed 2 h later by a probe trial
for short-term memory) and thereafter, we assessed short-term visual perceptual learning
[1 day, 4 trials, 15 min apart, 1 day of cue learning task (CUE)]. Qualitative and quantitative
analysis of performance was done by direct observation and analysis of videotape recorded
images and considering search and non-search strategies, as described [24,44,45].
Days 1–6, Spatial short- and long-term learning and memory (place learning of a
hidden platform): This place task (PT) consisted of progressive training of animals to find
the platform’s location until all the three experimental groups performed equally. The
procedure involved four trial sessions (T1-T4) per day, with trials spaced 15 min apart
(short-term memory) during 6 consecutive days (long-term memory). The mouse was
gently released (facing the wall) from one starting point randomly selected (N, S, E, or W)
and allowed to swim until they located the platform submerged 1.5 cm in a fixed position
(SW quadrant and 10 cm away from the wall). The escape latency was recorded. Mice that
failed to find the platform within 60 s were placed on it for 10 s, the same period that was
allowed for the successful animals.
Day 6, spatial short-term memory (removal): The short-term retention and level of
accuracy of the precise location of the platform position achieved were measured in a probe
trial or ‘removal’. One and a half hours after the last fourth trial of the place learning, the
platform was removed from the maze, and the mice performed a probe trial of 60 s.
Day 7, visual discrimination perceptual short-term learning and memory (cue learning
of a visual platform): In this task, the platform was elevated 1 cm above the water level,
with its position in the NW and indicated by a visible striped flag (5 × 8 × 15 cm), whereas
external maze cues were removed from the walls. Four trials spaced 15 min apart were
performed in one single day. The escape latency was recorded.
Quantitative analyses Behavior was evaluated by both direct observation and analysis
of videotape recorded images. Variables of time (escape latency, quadrant preference),
distance covered, and swimming speed were analyzed in all the tasks’ trials. The escape
latency was readily measured with a stopwatch by an observer unaware of the animal’s
genotype and confirmed during the subsequent video-tracking analysis. A video camera
placed above the water maze recorded the animal’s behavior, and thereafter, an automated
system (Smart, Panlab S.L., Barcelona, Spain) enabled computerized measurement of the
distance traveled by the animal during the trials. The swimming speed (cm/s) of the
mice during each trial was calculated. In the probe trial, the time spent in each of the four
quadrants, the distance traveled along with them and the number of crossings over the
removed platform position (annulus crossings) were also measured retrospectively using
the automated video-tracking analysis.
Qualitative analyses Strategy choice in the water maze reveals complex task-solving
cognitive paradigms, cognitive flexibility, and spatial learning, but it does not necessarily
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affect the escape latency or the distance [44]. Therefore, swimming strategies have been
extensively characterized by the features of their trajectories mostly based on their goal
or non-goal directionality [44]. In the present work, the swim paths for each mouse in
each trial of the cue learning task, place learning task, and probe trial were analyzed
following the swimming strategies described by Janus [44] and classified according to three
criteria: the goal or objective (non-search behaviors, namely floating and circling, vs. search
strategies), the direction (goal-directed vs. non-goal directed strategies) and the variety
(single vs. mixed strategies) as previously detailed [45].
2.4. Statistics
All the analyses were performed according to the SPSS (version 15.0) software. Results
are expressed as mean ± standard error of the mean (SEM) or as the incidence of behaviors.
Student t-test was used to compare differences between two independent groups. Paired
t-test was used for within-subjects pre-post comparison. In the different Morris water
maze tests, the factorial effects of T ‘treatment’, S ‘schedule’, D ’day’, t ‘trial’, and their
interactions were analyzed by Split Plot ANOVA for repeated measures followed by post-
hoc Bonferroni. Differences in the incidence were measured by Chi-square test. In all cases,
statistical significance was considered at p < 0.05.
3. Results
3.1. Presence of AD-Phenotype before Treatments
Before treatments, the presence of AD-phenotype was confirmed in the open-field test.
Thus, naïve 12-month-old 3xTg-AD mice showed poor horizontal (n = 42, 44.4 ± 13.3) and
vertical (n = 42, 9.1 ± 2.8) locomotor activities, as also compared to standard behavior of
age-matched NTg mice [30] (vs. n = 24, 93.5 ± 14.8, df 64, p < 0.01 and vs. n = 24, 22.5 ± 4.2,
df 64, p < 0.05, respectively). Thereafter, animals were distributed counterbalanced in the
three treatment groups, with no differences among them in these respects (all, p > 0.05) (see
Table 1, before treatment).
Table 1. Effects of HX and AVCRIP104P3 on BPSD-like behaviors in 3xTg-AD mice at advanced disease stages in each
group). Statistics: Student t-test, all n.s. p > 0.05 vs. the saline group; Paired t-test, a p < 0.05, aa p < 0.01vs. before treatment.
Saline
(n = 14)
Huprine X 0.12 µmol kg−1
(n = 14)
AVCRI104P3 0.6 µmol kg−1
(n = 14)
Mean ± SEM Mean ± SEM Mean ± SEM
Weight
% vs. initial weight 95.1 ± 1.7 92.8 ± 2.3 93.3 ± 1.5
Open field (before treatment)
Latency to leave the center (s) 10.79 ± 1.84 11.57 ± 2.03 13.07 ± 2.60
Latency to enter into the periphery (s) 36.50 ± 14.60 32.56 ± 6.48 26.93 ± 5.95
Total number of crossings 46.71 ± 8.62 49.50 ± 10.32 46.71 ± 10.30
Total number of rearings 10.57 ± 2.11 8.29 ± 2.14 9.50 ± 2.03
Number of groomings 2.29 ± 0.40 1.29 ± 0.19 0.71 ± 0.16
Incidence of defecations 13/14 12/14 13/14
Number of defecations 2.29 ± 0.30 2.07 ± 0.37 2.57 ± 0.45
Incidence of urinations 7/14 6/14 6/14
Presence of urine 0.57 ± 0.17 0.50 ± 0.17 0.57 ± 0.23
Open field (after treatment)
Latency to leave the center (s) 34.50 ± 13.05 13.00 ± 2.97 14.50 ± 1.92
Latency to enter into the periphery (s) 56.64 ± 23.50 39.79 ± 16.97 23.14 ± 4.77
Total number of crossings 32.29 ± 6.86 36.64 ± 8.68 a 36.43 ± 8.29
Total number of rearings 4.43 ± 1.01 aa 5.21 ± 1.43 6.07 ± 1.69 a
Number of groomings 1.14 ± 0.21 1.07 ± 0.20 1.29 ± 0.24 a
Incidence of defecations 13/14 14/14 12/14
Number of defecations 1.86 ± 0.35 2.07 ± 0.29 2.36 ± 0.52
Incidence of urinations 1/14 5/14 2/14
Presence of urine 0.7 ± 0.7 a 0.36 ± 0.13 0.29 ± 0.22




Huprine X 0.12 µmol kg−1
(n = 14)
AVCRI104P3 0.6 µmol kg−1
(n = 14)
Mean ± SEM Mean ± SEM Mean ± SEM
Dark/light box test
Latency to entry in the lit area (s) 134.29 ± 34.63 140.21 ± 34.05 1.88.29 ± 33.81
Time in the lit area (s) 13.00 ± 3.55 18.79 ± 7.93 15.57 ± 6.28
Number of entries 1.50 ± 0.45 1.93 ± 0.69 1.36 ± 0.43
Total number of risk assessment 3.57 ± 0.84 2.21 ± 0.43 2.43 ± 0.49
Total number of groomings 1.29 ± 0.30 1.36 ± 0.23 2.57 ± 0.91
Incidence of defecations 12/14 11/14 13/14
Number of defecations 2.07 ± 0.37 1.50 ± 0.33 1.79 ± 0.32
Incidence of urinations 6/14 9/14 8/14
Presence of urine 0.43 ± 0.14 1.00 ± 0.43 0.57 ± 0.14
Corner test
Number of visited corners 5.71 ± 0.87 6.21 ± 0.91 6.36 ± 0.68
Number of rearings 1.64 ± 0.55 3.14 ± 0.64 3.14 ± 0.67
3.2. Absence of Side Effects of AVCRIP104P3 and Huprine X
No side effects, such as tremulous jaw movements, or diarrhea, were observed through
treatment. At the end of the treatments, similar weight reduction was found in all the
groups (see Table 1, after treatment). When assessed in the open-field, the dark-light,
and the corner tests, all animals were found to perform equally, independently of the
treatment or assignment in a cognitive training schedule. The repeated OF test resulted
in the reduction of exploratory activity, which was stronger in saline-treated animals
(p = 0.007) with increased urination incidence (p = 0.02). AVCRI104P3 and HX-treated
mice showed moderated reduction of activity (rearings, 36%, p = 0.045 and crossings,
26%, p = 0.023, respectively). Increased grooming behavior (p = 0.040) was shown in
AVCRI104P3-treated mice.
3.3. Training Schedule Affected Learning and Memory
The ‘Day-by-day’ analysis (Figure 1A) showed acquisition curves (Day effect, D,
p < 0.05) in the place and cue learning tasks. Trial-by-trial analysis (Figure 1B) showed trial
(Trial effect, t, p < 0.05) but also schedule (S) and treatment (T) interaction effects (S × t,
T × S × t, S and T × S, all, p < 0.05) throughout the intervals of the six days of spatial
reference memory (PT1-PT6).
On their first experience in the MWM (T1, PT1), all groups used up the 60 s trial
duration. Only saline-treated 3xTg-AD mice trained at midday invested 60 s in the last
trial of that day (T4, PT1). Striking improvement of long-term memory was shown by
AVCRIP104P3 mice trained at midday on the next (T1, PT2) and third day (PT3). Thus,
in the first 24 h learning and memory trial (PT2, midday schedule), AVCRI104P3 showed
a 60% reduction of latency than the first trial performance, while saline and HX groups
were equally unsuccessful in finding the platform (mean latency 50 s). Huprine X reached
similar optimal performance on day 4 (PT4), and saline did so on day 5 (PT5). Performance
in the visual perceptual learning (CUE) was similar among groups and between schedules,
with improvements through consecutive repeated trials (T effect, p < 0.05).
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‘treatment × schedule’, S×t ‘schedule × trial’, T×S×t ‘treatment × schedule × trial’ effects, * 
p < 0.05. Post hoc Bonferroni: * p < 0.05 vs. the same schedule saline group, a p < 0.05 vs. 
the same schedule HX group, s p < 0.05 vs. the same treatment early morning training 
group. 
3.4. Training Schedule Affected Memory Retrieval 
Training schedule affected the probe trial’s performance (S, p < 0.0.5), which was bet-
ter in groups trained early morning. Impaired memory was only shown in saline-treated 
3xTg-AD mice trained at midday (TxS interaction effects, p < 0.05; post-hoc p < 0.05 only 
for saline). Saline-treated animals showed higher latency of annulus crossing (Figure 2A), 
used fewer goal-directed strategies, and exhibited non-search strategies (Figure 2B). 
Lower total number of annulus crossings (Figure 2C) and random search during the whole 
performance, with absolutely no preference for the trained quadrant (Figure 2D), were 
also recorded in saline-treated 3xTg-AD mice trained at midday. 
Figure 1. Effects of HX and AVCRIP104P3 on cognitive performance of 3xTg-AD mice in acquiring the place task and cue.
Results are expressed as mean ± SEM (n = 7 in each group). (A) Day-by-day total mean latency to reach a hidden (PTn) and
visible (CUE) platform. (B) Trial-by-tri l latency to reach the platform in e ch of the four trials (T1–T4) per session. Statistics:
Split plot ANOVA: T ‘treatment’, S ‘schedule’, D ‘day’, t ‘trial’, T × S ‘treatment × schedule’, S × t ‘schedule × trial’, T × S
× t ‘treatment × schedule × trial’ effects, * p < 0.05. Post hoc Bonferroni: * p < 0.05 vs. the same schedule saline group,
a p < 0.05 vs. the same schedule HX group, s p < 0.05 vs. the same treatment early morning training group.
3.4. Training Schedule Affected Memory Retrieval
Training schedule affected the probe trial’s perfor ance (S, p < 0.0.5), which was better
in groups trained early morning. Impaired memory was only shown in saline-treated 3xTg-
AD mice trained at midday (T × S interaction effects, p < 0.05; post-hoc p < 0.05 only for
saline). Saline-treated animals showed higher latency of annulus crossing (Figure 2A), used
fewer goal-directed strategies, and exhibited non-search strategies (Figure 2B). Lower total
number of annulus crossings (Figure 2C) and random search during the whole performance,
with absolutely no preference for the trained quadrant (Figure 2D), were also recorded in
saline-treated 3xTg-AD mice trained at midday.
Early schedule increased the accuracy of AVCRI104P3-treated mice in their search
for the platform, as shown by (1) the number of annulus crossings (Figure 2C) and (2) the
quantitative analysis of search and non-search strategies during the probe trial to assess
memory (Figure 2B) confirming the higher presence of goal-directed strategies resulting in
their improved response in AVCRI104P3-treated mice.
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ings, (D) time spent in each of the quadrants during the free swim trial: Platform, the trained 
quadrant where the platform was previously located, adjacent right, opposite and adjacent left 
quadrants. Time in random preference is indicated with dashed lines. Statistics: Split plot 
ANOVA: S ‘schedule’ effect, T × S ‘treatment × schedule’ interaction effects, * p < 0.05 with post 
hoc Bonferroni: * p < 0.05 vs. the same schedule saline group, s p < 0.05 vs. the same treatment 
early morning training group. 
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AD mouse model of the potent in vivo effects of AVCRIP104P3, a new multitarget drug, 
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4. Discussion
For the first time, the present study shows that the cognitive performance of 12-month-
old male 3xTg-AD mice in the MWM was sensitive to the training time schedule, with
the expected impaired performance modeling advanced stages of disease only shown in
saline-treated animals trained at midday. We also provide first evidence in an AD mouse
model of the potent in vivo effects of AVCRIP104P3, a new multitarget drug, as compared
to HX. Similar to HX, no side effects were induced by AVCRIP104P3. The streamlined
drug effectiveness of AVCRI104P3, with higher potency than its in vitro HX equipotent
dose, was stronger at mi day. The acquisition improvement w s sh wn in the long-term
memory and allowed a faster achiev ment of optimal performance already on the second
day of tr ining.
These results mostly accounted for the place task for spatial r ference learning and
memory and the subsequent hort-term memory perfor ance on he probe trial. There,
quadrant preferences and swim strategies used by the experimental groups confirmed
differ n cognitive approaches to solve the paradigm, the AD-cognitive dysfunction clearly
manifested in s line-tre ted animals trained at midday, and the enhanced performance in
early morning groups. In the single cue learning task for visual perceptual learning, which
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also records attentional and motivational aspects, all animals performed equally. However,
at midday, a trend to worse performance of saline-treated 3xTg-AD mice suggests that
short-term memory was affected, although animals could learn at the end of the day.
Regarding previous work in middle-aged mice, HX was shown to facilitate, in a dose-
dependent manner, learning and memory in the MWM [41] using goal-directed accurate
search strategies. The benefits were also seen in variables of emotionality and anxiety-like
behaviors and the lack of side effects nor affectation of motor activity. Similarly, both
ACVRI104P3 (0.06 µmol/kg) and in vitro equipotent dose of HX (0.12 µmol/kg) success-
fully improved the performance of cognitively poor middle-aged NTg male mice [30]. Both
drugs improved short-term learning and memory in a cued task, but ACVRI104P3 also
improved both short-term and long-term processes in the MWM and exerted anxiolytic
effects in the dark/light box test [30]. Finally, in 12-month-old 3xTg-AD mice, in vitro
equipotent doses of HX and HupA improved learning and memory in the MWM, with bet-
ter acquisition times, faster achievement of improved performance, as well as the presence
of goal-directed strategies, and more accurate discrimination of the trained platform in the
memory test. They did not induce adverse effects [42]. In the present work, the nootropic
effects exerted by HX and ACVRI104P3 in cognitively poor middle-aged mice [30,39] were
also confirmed as extensible to middle-aged 3xTg-AD mice. In contrast, the modulation of
emotional and anxiety-like behaviors shown in that work only translated to a moderate
effect. Both drugs’ benefits were seen independently of the training schedule but more
clearly in animals trained at midday.
It is important to note that the results were observed in two independent experimental
sets performed one month apart and that in each set, littermates were distributed in early
and midday schedules. Possible involvement of confounding factors was controlled. Thus,
animals reared and housed together were distributed into the three treatment groups, and
they exhibited similar basal BPSD-levels before treatment. Moreover, the performance
of the three groups of mice trained early in the morning was the same, as compared to
higher variability among groups at midday. Regarding circadian activity, circadian rhythm
disturbances have been reported by several research groups [20–29], with males better
showing these derangements [28]. We reported the overall lowest activity levels of 13-
month-old 3xTg-AD mice in their home cage in a 23 h (light and dark) circadian activity
compared to age-matched non-transgenic mice. In the particular time frame, from early
morning to midday (from 9 a.m. to 1 p.m.), activity levels were normal [24].
In the present work, the training protocol at midday involves sleep disruptions in
animals in the fourth hour of their non-active sleeping period. In contrast, the early morning
training schedule starts 1 h after the nocturnal activity and involves animals that are still
slowing down from their active phase of the circadian cycle [24]. We can hypothesize
that the active nocturnal period of rodents, which usually lasts some hours after the
switch of the lights, may benefit the level of neuronal activation required to accomplish
the task demands. In contrast, once the sleep pattern is achieved, sleep disruption helps
to reveal the low cognitive capacity of 3xTg-AD mice, while those animals receiving the
anticholinesterasic drugs can counteract these effects. This early sleep-wake cycle may also
benefit animals by enhancing the experience-dependent facilitator effect of corticosterone
on spatial memory formation in the water maze [47].
The present behavioral evidence meets the growing interest on the crosstalk of the
sleep-waves cycle and learning and memory in AD and alerts about the pertinence of
taking into account methodological issues relevant to it. The results open a question of how
time schedules modulate the capacity to respond to task demands and elucidate new drug
effectiveness. Further research should also consider female scenarios, where the lower
circadian rhythms disruption may also unveil compensatory mechanisms and modulation
by extrinsic pharmacological-related factors.
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